Single dose study for liver health
Part of Infections clinical trials.
This trial tests a single dose of an experimental drug called pevifoscorvir in people with moderate liver problems and in healthy people. It aims to see how the body processes the drug and if it is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 75 years old
- Weigh more than 110 pounds with a BMI between 17.5 and 40
- Have either normal liver function or moderate liver impairment (Child-Pugh class B)
- Agree to use effective birth control if you could become pregnant or get someone pregnant
- Be willing to avoid alcohol for 48 hours before the study until the end
- Not have unstable heart disease, drug/alcohol abuse, or active infections like hepatitis or HIV
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the medicine PF-07328948 is processed by people with different levels of liver function. It includes both healthy people and those with stable liver disease (classified as mild, moderate, or severe). The goal is to see if the liver condition affects how the drug works in the body.
This Phase 1 study tests how two investigational medicines move through the body and how safe they are in people with different levels of liver impairment, compared with healthy volunteers. It may help doctors understand dosing and safety for people with liver problems.
This is an early-stage study testing a new medicine called PF-08653944 in healthy adults and in people with varying degrees of liver function problems. The goal is to understand how the medicine works in the body and how liver function affects how the body processes it.
This trial tests a combination of three drugs (BRII-179, BRII-835, and PEG-IFNα) to see if they can better control chronic hepatitis B. It is for people who are already on antiviral therapy and have well-controlled virus levels.
This trial tests a new medicine (VIR-2218) combined with a standard injection (peginterferon) to see if it can better control chronic hepatitis B. It may be an option if your virus levels are low and you haven't had recent treatment.
This trial tests how a drug (BMS-986435) behaves in people with normal liver function versus those with liver problems. It also checks that the drug is safe for the heart.
Hear when a new Chronic Hepatitis B Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.